胰激肽原酶片对早期糖尿病肾病疗效观察

目的:评价胰激肽原酶片治疗早期糖尿病肾病患者的疗效和安全性.方法:将82例早期糖尿病肾病患者随机分成2组,采用糖尿病饮食控制、体育锻炼及根据病情给予口服降糖药物或/和胰岛素治疗,治疗组(42例)加用胰激肽原酶片治疗4周.观察治疗前后尿微量白蛋白与24h尿蛋白定量和不良反应.结果:治疗组治疗前后尿微量白蛋白与24h尿蛋白定量明显降低,差异有统计学意义(P<0.01);对照组治疗前后比较差异无统计学意义(P>0.05);组间比较差异有统计学意义(P<0.01);2组患者无明显的药物不良反应.结论:胰激肽原酶片治疗早期糖尿病肾病患者疗效好,用药安全,可广泛应用于临床.

Therapeutic Effect of Pancreatic Kininogenase Tablets on Early Stage Diabetic Nephropathy

Objective:To evaluate the efficacy and safety of the pancreatic kininogenase tablets in treating early stage diabetic nephropathy.Methods:82 early stage diabetic nephropathy patients were divided randomly into 2 groups,In addition to dietary control,physical exercise,and admin-istrating with oral antidiabetic drugs according to the condition and/or insulin treatment,pancreatic kininogenase tablets were given to the patients of the test group for 4 weeks,micro-quantity urine albumin,24h quantity of urine protein and ADR were observed before and after the treatment.Results:The urine micro-quantity albumin and quantity of 24 h urine protein of the test group deceased after treatment with significant difference(P < 0.01),no significant difference was found of the control group before and after the treatment(P > 0.05),the difference between groups was significant,too(P < 0.01).No distinct ADR was found.Conclusion:Pancreatic kininogenase tablets are effective and safe in the treatment of early stage diabetic nephropathy,which can be widely used in clinical treatment.